Bloom Burton analyst David Martin PhD has maintained their neutral stance on RPTX stock, giving a Hold rating on January 10.Stay Ahead of the ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...

Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...

One of the two North Korean soldiers captured by Ukraine has claimed during questioning that he thought he was going for training, not to the war against Ukraine, Kyiv's security s... The former head ...